pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-4656 |
Genomic Coordinates | chr7: 4788565 - 4788639 |
Description | Homo sapiens miR-4656 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-4656 | ||||||||||||||||||||||||||||||
Sequence | 10| UGGGCUGAGGGCAGGAGGCCUGU |32 | ||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||
Experiments | Illumina | ||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SLC10A3 | ||||||||||||||||||||
Synonyms | DXS253E, P3 | ||||||||||||||||||||
Description | solute carrier family 10 member 3 | ||||||||||||||||||||
Transcript | NM_001142391 | ||||||||||||||||||||
Other Transcripts | NM_001142392 , NM_019848 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SLC10A3 | |||||||||||||||||||||
3'UTR of SLC10A3 (miRNA target sites are highlighted) |
>SLC10A3|NM_001142391|3'UTR 1 GGCCTCTGGGTCAAGCTTTCATCAGCCCCAGCCCCCACACTCCACCAAAGTTCTCATGCACTATGCACTCAGAAAAATCC 81 AGGCTTATTTTTTTTACTGATTTTTTATTCTCCAGCTTTCAGTGCCAAAGAGGCCATGCTGAGTTAGGTAGGTGGGCGCT 161 GCCCAGAAAATATATTTCAATAAAAGAGAGAAGCAAGCTTGAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | BC-1 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796037. RNA binding protein: AGO2. Condition:4-Thiouridine
PAR-CLIP data was present in GSM796038. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Prostate Tissue |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760620. RNA binding protein: AGO2. Condition:AGO-CLIP-LAPC4_A
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM796037 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-1 / 4-Thiouridine |
Location of target site | ENST00000369649.4 | 3UTR | UCAAGCUUUCAUCAGC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM796038 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-1 / 4-Thiouridine |
Location of target site | ENST00000369649.4 | 3UTR | UCAAGCUUUCAUCAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
48 hsa-miR-4656 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT135536 | RAB5B | RAB5B, member RAS oncogene family | 2 | 2 | ||||||||
MIRT168127 | SOX4 | SRY-box 4 | 2 | 2 | ||||||||
MIRT301229 | SH3BP4 | SH3 domain binding protein 4 | 2 | 2 | ||||||||
MIRT444362 | TIMM8B | translocase of inner mitochondrial membrane 8 homolog B | 2 | 2 | ||||||||
MIRT445909 | SLC10A3 | solute carrier family 10 member 3 | 2 | 2 | ||||||||
MIRT447283 | LAPTM5 | lysosomal protein transmembrane 5 | 2 | 2 | ||||||||
MIRT453797 | KBTBD12 | kelch repeat and BTB domain containing 12 | 2 | 2 | ||||||||
MIRT456777 | MTHFSD | methenyltetrahydrofolate synthetase domain containing | 2 | 2 | ||||||||
MIRT459647 | PCSK9 | proprotein convertase subtilisin/kexin type 9 | 2 | 2 | ||||||||
MIRT462333 | BCL7B | BCL tumor suppressor 7B | 2 | 2 | ||||||||
MIRT463535 | ZBTB7A | zinc finger and BTB domain containing 7A | 2 | 2 | ||||||||
MIRT465799 | TMEM91 | transmembrane protein 91 | 2 | 2 | ||||||||
MIRT470647 | POM121C | POM121 transmembrane nucleoporin C | 2 | 2 | ||||||||
MIRT470837 | PLXND1 | plexin D1 | 2 | 2 | ||||||||
MIRT471129 | PHF19 | PHD finger protein 19 | 2 | 2 | ||||||||
MIRT483310 | SLC35C2 | solute carrier family 35 member C2 | 2 | 2 | ||||||||
MIRT487264 | CCNF | cyclin F | 2 | 2 | ||||||||
MIRT491731 | SEMA3F | semaphorin 3F | 2 | 2 | ||||||||
MIRT497195 | DRP2 | dystrophin related protein 2 | 2 | 2 | ||||||||
MIRT508384 | SPTBN2 | spectrin beta, non-erythrocytic 2 | 2 | 4 | ||||||||
MIRT530496 | FADS6 | fatty acid desaturase 6 | 2 | 2 | ||||||||
MIRT546995 | PPP2CA | protein phosphatase 2 catalytic subunit alpha | 2 | 2 | ||||||||
MIRT549790 | KIAA0391 | KIAA0391 | 2 | 2 | ||||||||
MIRT560368 | TAF8 | TATA-box binding protein associated factor 8 | 2 | 2 | ||||||||
MIRT566000 | RNF4 | ring finger protein 4 | 2 | 2 | ||||||||
MIRT574035 | PEX26 | peroxisomal biogenesis factor 26 | 2 | 2 | ||||||||
MIRT574231 | DMRT2 | doublesex and mab-3 related transcription factor 2 | 2 | 2 | ||||||||
MIRT576139 | Hmox1 | heme oxygenase 1 | 2 | 2 | ||||||||
MIRT576640 | Mill2 | MHC I like leukocyte 2 | 1 | 1 | ||||||||
MIRT609875 | RAD54L2 | RAD54 like 2 | 2 | 4 | ||||||||
MIRT622651 | POU2F3 | POU class 2 homeobox 3 | 2 | 4 | ||||||||
MIRT628848 | FAM151B | family with sequence similarity 151 member B | 2 | 2 | ||||||||
MIRT634252 | TIAL1 | TIA1 cytotoxic granule associated RNA binding protein like 1 | 2 | 2 | ||||||||
MIRT634672 | GDE1 | glycerophosphodiester phosphodiesterase 1 | 2 | 2 | ||||||||
MIRT649087 | FBXO25 | F-box protein 25 | 2 | 2 | ||||||||
MIRT665019 | ELK1 | ELK1, ETS transcription factor | 2 | 2 | ||||||||
MIRT666939 | PMEPA1 | prostate transmembrane protein, androgen induced 1 | 2 | 2 | ||||||||
MIRT668960 | CNBP | CCHC-type zinc finger nucleic acid binding protein | 2 | 2 | ||||||||
MIRT675802 | MED28 | mediator complex subunit 28 | 2 | 2 | ||||||||
MIRT684022 | FOLR1 | folate receptor 1 | 2 | 2 | ||||||||
MIRT696480 | COX6B1 | cytochrome c oxidase subunit 6B1 | 2 | 2 | ||||||||
MIRT705894 | ADCY9 | adenylate cyclase 9 | 2 | 2 | ||||||||
MIRT709434 | ZSCAN25 | zinc finger and SCAN domain containing 25 | 2 | 2 | ||||||||
MIRT713572 | SLC2A8 | solute carrier family 2 member 8 | 2 | 2 | ||||||||
MIRT716697 | HLA-B | major histocompatibility complex, class I, B | 2 | 2 | ||||||||
MIRT719735 | SLC39A11 | solute carrier family 39 member 11 | 2 | 2 | ||||||||
MIRT724907 | DAO | D-amino acid oxidase | 2 | 2 | ||||||||
MIRT725321 | NFASC | neurofascin | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|